Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis
Open accessThe DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in western countries. Despite the high prevalence of NAFLD, the underlying biology of the disease progression is not clear, and there are no approved drugs to treat non-alcoholic steatohepatitis (NASH), the most advanced form of the disease. Thus, there is an urgent need for developing advanced in vitro human cellular systems to study disease mechanisms and drug responses. We attempted to create an organoid system genetically predisposed to NAFLD and to induce steatosis and fibrosis in it by adding free fatty acids. We used multilineage 3D spheroids composed by hepatocytes (HepG2) and hepatic stellate cells (LX-2) with a physiological ratio (24:1). HepG2 and LX-2 cells are homozygotes for the PNPLA3 I148M sequence variant, the strongest genetic determinant of NAFLD. We demonstrate that hepatic stellate cells facilitate the compactness of 3D spheroids. Then, we show that the spheroids develop accumulations of fat and collagen upon exposure to free fatty acids. Finally, this accumulation was rescued by incubating spheroids with liraglutide or elafibranor, drugs that are in clinical trials for the treatment of NASH. In conclusion, we have established a simple, easy to handle, in vitro model of genetically induced NAFLD consisting of multilineage 3D spheroids. This tool may be used to understand molecular mechanisms involved in the early stages of fibrogenesis induced by lipid accumulation. Moreover, it may be used to identify new compounds to treat NASH using high-throughput drug screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MASLD modeling using co-cultures aims to reproduce the tissue microenvironment of the liver, including intercellular interactions between hepatocytes and non-parenchymal cells (stellate, immune), which is a key factor in the progression from steatosis to steatohepatitis and fibrosis [132,133,134].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [132]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In more complex systems (3D cultures, co-cultures), lower FFA concentrations (10–500 μM) are required [131,132,133,134], which brings conditions closer to physiological ones and reduces the risk of non-specific cytotoxicity.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [132]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For genetic studies of PNPLA3-dependent mechanisms, HepG2 + LX-2 3D spheroids [132] utilizing endogenous PNPLA3 I148M homozygosity serve as a unique platform.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [132]
In the citing paper
“Co-culturing cells using conventional 2D methods or in 3D spheroids allows for functional characterisation of these interactions,14 but is hampered by the poor reproduction of the environment that drives NASH in vivo, with investigations often limited to 2 subpopulations rather than the multicellular environment.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 1×
“NAFLD encompasses a wide spectrum of pathologic conditions, including hepatic steatosis and non-alcoholic steatohepatitis (NASH), which can further progress to fibrosis, cirrhosis and hepatocellular carcinoma [2].”
BackgroundMechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · cited 2×
“We found an increase in collagen levels after fatty acids treatment and as expected after treatment with TGF-β [48–50] the most potent fibrogenic cytokine [20].”
BackgroundHepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“However, after liver injury HSCs transdifferentiate and start producing extracellular matrix (ECM) proteins [17,19,21,22].”
BackgroundThe third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817 · cited 1×
“For instance, 3D cell cultures represent more closely the heterogeneous cell–cell interactions and offer a more similar micro-environment to the in vivo situation with respect to cell shape, adhesion, behavior, topology, and morphology [14].”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · cited 1×
“Of note, clinical studies show how severe fibrosis is the best predictor of mortality in patients with NAFLD [16].”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942 · cited 1×
“TGF-β is critical for the activation of fibrogenic myofibroblasts, which in response to injury upregulate α-smooth muscle actin (α-SMA) and secrete extracellular matrix proteins, mostly collagen Type I [38,39].”
BackgroundFrom 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834 · cited 1×
“This need has led to generation of more complex 3D in vitro models that have generated great attention [13].”
BackgroundThe burden of liver disease in Europe: A review of available epidemiological data
Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.-C., & Roudot-Thoraval, F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.005 · Cited by 1,341
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818 · cited 11×
“Finally, this accumulation was rescued by incubating spheroids with liraglutide or elafibranor, drugs currently evaluated in clinical trials for the treatment of NASH and associated fibrosis.”
BackgroundInfluentialHepatic stellate cells in liver development, regeneration, and cancer
Yin, C., Evason, K. J., Asahina, K., & Stainier, D. Y. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66369 · Cited by 719 · cited 1×
“This is consistent with the localization of stellate cells in the space of Disse, a small area between the sinusoids and hepatocytes, in human liver [53].”
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690 · cited 1×
“This result is consistent with human studies showing that hepatic lipoprotein secretion increases with the increase of liver fat content [43].”
ResultRecent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573 · cited 12×
“Finally, this accumulation was rescued by incubating spheroids with liraglutide or elafibranor, drugs currently evaluated in clinical trials for the treatment of NASH and associated fibrosis.”
BackgroundInfluentialGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Hepatic Stellate Cells and Liver Fibrosis
Moreira, R. K. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-1728-hscalf · Cited by 452
Gene Expression Profiles During Hepatic Stellate Cell Activation in Culture and In Vivo
De Minicis, S., Seki, E., Uchinami, H., Kluwe, J., Zhang, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.033 · Cited by 426 · cited 1×
“TGF-β is critical for the activation of fibrogenic myofibroblasts, which in response to injury upregulate α-smooth muscle actin (α-SMA) and secrete extracellular matrix proteins, mostly collagen Type I [38,39].”
BackgroundStatin use and non-alcoholic steatohepatitis in at risk individuals
Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R. M., Pipitone, R., Karja, V., Maggioni, M., Kakela, P., Wiklund, O., Mozzi, E., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.006 · Cited by 390 · cited 1×
“They also display a diverse response to statins [33], fenofibrate and omega 3 fatty acids [34,35] and present more hepatotoxicity after treatment for leukemia [36].”
BackgroundSelf-citationDongiovanni, P., Stender, S., Pietrelli, A., Mancina, R. M., Cespiati, A., Petta, S., Pelusi, S., Pingitore, P., Badiali, S., Maggioni, M., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12719 · Cited by 367 · cited 1×
“Moreover, we have shown a causal role of liver fat in generating fibrosis by using Mendelian randomization in humans [8].”
BackgroundSelf-citationPNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells
Pirazzi, C., Valenti, L., Motta, B. M., Pingitore, P., Hedfalk, K., Mancina, R. M., Burza, M. A., Indiveri, C., Ferro, Y., Montalcini, T., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu121 · Cited by 363 · cited 1×
“HepG2 cells are homozygotes for the PNPLA3 I148M sequence variant, the strongest genetic determinant of NAFLD [23] expressed at high levels in both hepatocytes and hepatic stellate cells [28,29].”
BackgroundSelf-citationAdiponutrin Functions as a Nutritionally Regulated Lysophosphatidic Acid Acyltransferase
Kumari, M., Schoiswohl, G., Chitraju, C., Paar, M., Cornaciu, I., Rangrez, A. Y., Wongsiriroj, N., Nagy, H. M., Ivanova, P. T., Scott, S. A., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.008 · Cited by 316 · cited 2×
“Studies in murine models showed that the PNPLA3 I148M sequence variation induces an increase in the lipogenic activity [24] and that downregulation of the protein is protective against NAFLD [25–27].”
BackgroundCARPINO, G., MORINI, S., GINANNICORRADINI, S., FRANCHITTO, A., MERLI, M., SICILIANO, M., GENTILI, F., ONETTIMUDA, A., BERLOCO, P., & ROSSI, M. (2005) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.11.009 · Cited by 309 · cited 1×
“However, after liver injury HSCs transdifferentiate and start producing extracellular matrix (ECM) proteins [17,19,21,22].”
BackgroundPirazzi, C., Adiels, M., Burza, M. A., Mancina, R. M., Levin, M., Ståhlman, M., Taskinen, M.-R., Orho-Melander, M., Perman, J., Pujia, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.030 · Cited by 305 · cited 2×
“Moreover, carriers of the PNPLA3 I148M variant have several specific characteristics including a lower hepatic VLDL secretion [27], lower turnover of retinol in stellate cells [28–31] and a specific signature of circulating lipids [32].”
BackgroundSelf-citationImmunoglobulin treatment reduces atherosclerosis in apo E knockout mice.
Nicoletti, A., Kaveri, S., Caligiuri, G., Bariéty, J., & Hansson, G. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119892 · Cited by 301 · cited 1×
“The total area of ORO-stained lipid droplets was determined as previously described [60].”
MethodModelling tissues in 3D: the next future of pharmaco-toxicology and food research?
Mazzoleni, G., Di Lorenzo, D., & Steimberg, N. (2009) · Genes & Nutrition · doi:10.1007/s12263-008-0107-0 · Cited by 253 · cited 1×
“However, 2D cultures do not represent the complexity of human tissues [11], while in vivo animal models often do not mirror human disease due to interspecies differences [12].”
BackgroundLindén, D., Ahnmark, A., Pingitore, P., Ciociola, E., Ahlstedt, I., Andréasson, A.-C., Sasidharan, K., Madeyski-Bengtson, K., Zurek, M., Mancina, R. M., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.01.013 · Cited by 211 · cited 1×
“Studies in murine models showed that this sequence variation increases lipid biosynthesis [24] and that its downregulation is beneficial against fatty liver disease [25,26].”
BackgroundSelf-citationKocabayoglu, P., Lade, A., Lee, Y. A., Dragomir, A.-C., Sun, X., Fiel, M. I., Thung, S., Aloman, C., Soriano, P., Hoshida, Y., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.036 · Cited by 184 · cited 1×
“PDGF is a potent factor involved in stimulating HSC proliferation, differentiation, and migration [40].”
BackgroundAnkoma-Sey, V., & Friedman, S. L. (1998) · Liver Growth and Repair · doi:10.1007/978-94-011-4932-7_20 · Cited by 173 · cited 1×
“Stellate cells are the major hepatic cells capable of upregulating COL1A1 mRNA following a fibrogenic stimulus [51].”
BackgroundHuman hepatic 3D spheroids as a model for steatosis and insulin resistance
Kozyra, M., Johansson, I., Nordling, Å., Ullah, S., Lauschke, V. M., & Ingelman-Sundberg, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-32722-6 · Cited by 173 · cited 2×
“To study NAFLD, in the last decades, several in vitro as well as in vivo models for liver disease and drug discovery have been developed [5,9,10].”
BackgroundResultMilani, S., Herbst, H., Schuppan, D., Surrenti, C., Riecken, E. O., & Stein, H. (1990) · Europe PMC (PubMed Central) · Cited by 171
Pan, X., Chen, Z., Huang, R., Yao, Y., & Ma, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060335 · Cited by 164
Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth?
Hadi, H., Vettor, R., & Rossato, M. (2018) · Antioxidants · doi:10.3390/antiox7010012 · Cited by 150
Reeves, H. L., Burt, A. D., Wood, S. M., & Day, C. P. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80238-8 · Cited by 146
PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis
Pingitore, P., Dongiovanni, P., Motta, B. M., Meroni, M., Lepore, S. M., Mancina, R. M., Pelusi, S., Russo, C., Caddeo, A. M., Rossi, G. E., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw341 · Cited by 144 · cited 1×
“HepG2 cells are homozygotes for the PNPLA3 I148M sequence variant, the strongest genetic determinant of NAFLD [23] expressed at high levels in both hepatocytes and hepatic stellate cells [28,29].”
BackgroundSelf-citationEffect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease
Chavez-Tapia, N. C., Rosso, N., & Tiribelli, C. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-20 · Cited by 137 · cited 1×
“showed that fat-laden hepatocytes have a pivotal role in the initiation of liver fibrosis [45].”
BackgroundHepatic adaptations to maintain metabolic homeostasis in response to fasting and refeeding in mice
Geisler, C. E., Hepler, C., Higgins, M. R., & Renquist, B. J. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0122-x · Cited by 135
Tølbøl, K. S., Kristiansen, M. N., Hansen, H. H., Veidal, S. S., Rigbolt, K. T., Gillum, M. P., Jelsing, J., Vrang, N., & Feigh, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i2.179 · Cited by 134 · cited 1×
“showed that liraglutide only improved steatosis in a diet specific manner in DIO-NASH mice while elafibranor and obeticholic acid reduced both hepatic steatosis and inflammation and only elafibranor reduced fibrosis severity [57].”
BackgroundThe role of PNPLA3 in health and disease
Pingitore, P., & Romeo, S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.06.018 · Cited by 128 · cited 2×
“HepG2 cells are homozygotes for the PNPLA3 I148M sequence variant, the strongest genetic determinant of NAFLD [23] expressed at high levels in both hepatocytes and hepatic stellate cells [28,29].”
BackgroundSelf-citationScorletti, E., West, A. L., Bhatia, L. S., Hoile, S. P., McCormick, K. G., Burdge, G. C., Lillycrop, K. A., Clough, G. F., Calder, P. C., & Byrne, C. D. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.036 · Cited by 124 · cited 1×
“They also display a diverse response to statins [33], fenofibrate and omega 3 fatty acids [34,35] and present more hepatotoxicity after treatment for leukemia [36].”
BackgroundMondul, A. M., Mancina, R. M., Merlo, A., Dongiovanni, P., Rametta, R., Montalcini, T., Valenti, L. V. C., Albanes, D., & Romeo, S. (2015) · Journal of Nutrition · doi:10.3945/jn.115.210633 · Cited by 119
Self-citationSong, Y., Kim, S.-H., Kim, K. M., Choi, E. K., Kim, J., & Seo, H. R. (2016) · Scientific Reports · doi:10.1038/srep36750 · Cited by 117 · cited 3×
“[17], co-culture of HepG2 with LX-2 enhanced the compactness of spheroids.”
BackgroundOscarsson, J., Önnerhag, K., Risérus, U., Sundén, M., Johansson, L., Jansson, P.-A., Moris, L., Nilsson, P. M., Eriksson, J. W., & Lind, L. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.08.003 · Cited by 112 · cited 1×
“They also display a diverse response to statins [33], fenofibrate and omega 3 fatty acids [34,35] and present more hepatotoxicity after treatment for leukemia [36].”
BackgroundLiver fibrosis in vitro: Cell culture models and precision-cut liver slices
van de Bovenkamp, M., Groothuis, G. M. M., Meijer, D. K. F., & Olinga, P. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2006.12.009 · Cited by 110 · cited 1×
“However, 2D cultures do not represent the complexity of human tissues [11], while in vivo animal models often do not mirror human disease due to interspecies differences [12].”
BackgroundSurvival advantages of multicellular spheroids vs. monolayers of HepG2 cells in vitro
Li (1994) · Oncology Reports · doi:10.3892/or_00000167 · Cited by 100 · cited 1×
“3D culture systems have recently gained significant attention as a more reliable in vitro system for studying various molecular processes and screening of therapeutic agents [42].”
BackgroundKumashiro, N., Yoshimura, T., Cantley, J. L., Majumdar, S. K., Guebre-Egziabher, F., Kursawe, R., Vatner, D. F., Fat, I., Kahn, M., Erion, D. M., et al. (2013) · Hepatology · doi:10.1002/hep.26170 · Cited by 89 · cited 1×
“Studies in murine models showed that this sequence variation increases lipid biosynthesis [24] and that its downregulation is beneficial against fatty liver disease [25,26].”
BackgroundNon-alcoholic fatty liver disease (NAFLD) models in drug discovery
Cole, B. K., Feaver, R. E., Wamhoff, B. R., & Dash, A. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1410135 · Cited by 85 · cited 2×
“To understand molecular mechanisms of NAFLD and to identify new drugs several in vitro models of fatty liver disease based on 2D cell culture and in vivo mouse models have been exploited [9,10].”
BackgroundThe interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH
Barbero-Becerra, V. J., Giraudi, P. J., Chávez-Tapia, N. C., Uribe, M., Tiribelli, C., & Rosso, N. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.07.010 · Cited by 71 · cited 6×
“The activation of HSCs after liver injury leads to production of extracellular matrix (ECM) [15] leading to fibrosis and ultimately cirrhosis.”
BackgroundInfluentialAn Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present
Jacobs, A., Warda, A., Verbeek, J., Cassiman, D. M., & Spincemaille, P. (2016) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.3 · Cited by 64 · cited 2×
“To understand molecular mechanisms of NAFLD and to identify new drugs several in vitro models of fatty liver disease based on 2D cell culture and in vivo mouse models have been exploited [9,10].”
BackgroundHyysalo, J., Gopalacharyulu, P., Bian, H., Hyötyläinen, T., Leivonen, M., Jaser, N., Juuti, A., Honka, M.-J., Nuutila, P., Olkkonen, V. M., et al. (2014) · Diabetes · doi:10.2337/db13-0774 · Cited by 62 · cited 2×
“Moreover, carriers of the PNPLA3 I148M variant have several specific characteristics including a lower hepatic VLDL secretion [27], lower turnover of retinol in stellate cells [28–31] and a specific signature of circulating lipids [32].”
BackgroundKovářová, M., Königsrainer, I., Königsrainer, A., Machicao, F. E., Häring, H., Schleicher, E. D., & Peter, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2978 · Cited by 60
Giraudi, P. J., Barbero-Becerra, V. J., Marin, V., Chávez-Tapia, N. C., Tiribelli, C., & Rosso, N. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.12.006 · Cited by 58 · cited 1×
“showed that COL1A1 levels were increased in a 2D co-culture model of hepatocytes and stellate cells after free fatty acids exposure [46].”
BackgroundLiu, Y., Fernandez, C., Smith, C., Yang, W., Cheng, C., Panetta, J., Kornegay, N., Liu, C., Ramsey, L., Karol, S., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.629 · Cited by 58 · cited 1×
“They also display a diverse response to statins [33], fenofibrate and omega 3 fatty acids [34,35] and present more hepatotoxicity after treatment for leukemia [36].”
BackgroundInsulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells
Sokolović, A., Sokolović, M., BOERS, W., Elferink, R. P. J. O., & Bosma, P. J. (2010) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-3-3 · Cited by 53 · cited 1×
“However, after liver injury HSCs transdifferentiate and start producing extracellular matrix (ECM) proteins [17,19,21,22].”
BackgroundBrenner, D. A., Veloz, L., Jaenisch, R., & Alcorn, J. M. (1993) · Hepatology · doi:10.1002/hep.1840170220 · Cited by 53
Johnston, E. F., & Gillis, T. E. (2017) · Journal of Experimental Biology · doi:10.1242/jeb.160093 · Cited by 51
Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells
Xu, N., Hurtig, M., Zhang, X., Ye, Q., & Nilsson‐Ehle, P. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2004.04.001 · Cited by 45 · cited 1×
“where TGF-β significantly inhibited both APOM and APOB mRNA expression in HepG2 cells [44].”
BackgroundFinkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 44
Weiskirchen, R., & Friedman, S. L. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3207-9 · Cited by 39
Seet, L., Toh, L. Z., Chu, S. W. L., Finger, S. N., Chua, J., & Wong, T. T. L. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.028555 · Cited by 33 · cited 1×
“Type I collagen, the major component of extracellular matrix (ECM) and the most abundant form of collagen in the body, is the most frequently measured collagen component of scar proteins [47].”
BackgroundMadhu, D., Hammad, M. M., Kavalakatt, S., Khadir, A., & Tiss, A. (2017) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201600169 · Cited by 9
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“, 2020), or spheroids using cell lines (Pingitore et al., 2019) offers the prospect of dissecting these interactions and establishing a platform for highthroughput testing of candidate therapeutic agents.”
BackgroundLiver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Cherubini, A., Ostadreza, M., Jamialahmadi, O., Pelusi, S., Rrapaj, E., Casirati, E., Passignani, G., Norouziesfahani, M., Sinopoli, E., Baselli, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02553-8 · Cited by 136
“Finally, to test a causal role of ER-α-dependent induction of steatosis on fibrosis development, HepG2 cells were cocultured with human immortalized hepatic stellate cells (LX-2, homozygous for the p.I148M variant) to generate three-dimensional (3D) multilineage hepatic spheroids 45 .”
MethodSelf-citationTanaka, Y., Shimanaka, Y., Caddeo, A., Kubo, T., Mao, Y., Kubota, T., Kubota, N., Yamauchi, T., Mancina, R. M., Baselli, G., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320646 · Cited by 132
Self-citationLiver-on-a-Chip models of fatty liver disease
Hassan, S., Sebastian, S., Maharjan, S., Lesha, A., Carpenter, A., Liu, X., Xie, X., Livermore, C., Zhang, Y. S., & Zarrinpar, A. (2020) · Hepatology · doi:10.1002/hep.31106 · Cited by 127
“Hepatic spheroids recreate 3D liver tissues resembling native structure and function, including fat accumulation and collagen deposition.(5,6) However, they are typically static and limited in architecture and incorporation of multiple cell types.”
Background
Metadata
- Authors
- Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S.
- Affiliations
- University of Gothenburg (SE)
- AstraZeneca (Sweden) (SE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Romeo, Stefano
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-04-02
- Volume
- 20
- Issue
- 7
- Pages
- 1629
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6480107
- OpenAlex
- W2935565749
- Cited by
- 152
- References
- 64
- Citations by year
- 2026: 28 · 2025: 22 · 2024: 19 · 2023: 23 · 2022: 22 · 2021: 16 · 2020: 19 · 2019: 2
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Vetenskapsrådet (2016-01527)
- Hjärt-Lungfonden (20120533)
- the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (SU 2018-04276)
- Novonordisk Foundation Grant for Excellence in Endocrinology (Excellence Project, 9321-430)
- Swedish Diabetes Foundation (DIA 2017-205)
- Research grant from AstraZeneca (Echo Project, 10033852)
- Wallenberg Academy Fellows from the Knut and Alice Wallenberg Foundation (KAW 2017.0203)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic steatosis, liver fibrosis, multicellular spheroids, organoids, PNPLA3 I148M, HepG2 cells, LX-2 cells, hepatic stellate cells, hepatocytes, free fatty acids, liraglutide, elafibranor, in vitro disease model, drug screening
- MeSH terms
- Liraglutide, Apolipoproteins B, Fatty Acids, Humans, Liver Cirrhosis, Models, Biological, Propionates, Spheroids, Cellular, Coculture Techniques, Cell Lineage, Collagen Type I, Chalcones, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.